Tigecycline's Primary Mechanism on Enzyme Levels
Tigecycline, a glycylcycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking tRNA entry and halting translation. This does not directly target enzyme levels but indirectly reduces levels of bacterial enzymes reliant on new protein production, such as beta-lactamases in resistant strains like Acinetobacter baumannii or Klebsiella pneumoniae. Studies show tigecycline lowers beta-lactamase expression by starving bacteria of enzyme-synthesizing machinery [1].
Effects on Host Liver Enzymes
Tigecycline elevates liver enzymes in patients, with clinical trials reporting increased ALT (alanine aminotransferase) by 5-10 times upper normal limit in 10-15% of cases, and AST (aspartate aminotransferase) similarly affected. This hepatotoxicity arises from mitochondrial dysfunction in hepatocytes, impairing oxidative phosphorylation and enzyme release. Elevations peak 7-14 days into IV therapy (50 mg every 12 hours) and resolve post-discontinuation in most [2][3].
Impact on Cytochrome P450 Enzymes
Tigecycline weakly induces CYP3A4 in vitro but shows no clinically significant effect on CYP1A2, CYP2C9, CYP2C19, or CYP2D6 in human studies. It does not alter levels of these drug-metabolizing enzymes meaningfully, allowing safe co-administration with most CYP substrates without dose adjustments [4].
Clinical Monitoring and Risk Factors
Monitor ALT/AST weekly during treatment, especially in patients with liver impairment or prolonged use (>14 days). Risk factors include obesity (higher AUC exposure) and combo therapy with hepatotoxins. No direct influence on renal enzymes like creatinine kinase [2][5].
Sources:
[1] Antimicrob Agents Chemother, 2007
[2] Tygacil FDA Label
[3] Clin Infect Dis, 2009
[4] Drug Metab Dispos, 2006
[5] StatPearls, 2023